Abbott Laboratories, founded in 1888 and headquartered in Abbott Park, Illinois, United States, is a diversified global healthcare company offering diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. The company reported revenues over $43 billion in fiscal 2022, supported by innovative products like the FreeStyle Libre and Alinity diagnostic platforms. Under the leadership of CEO Robert B. Ford since March 2020, Abbott has strengthened its position in more than 160 countries. Looking ahead, it is investing in next-generation digital health and expanding its global footprint to meet evolving market needs.
Financial Statements
In thousands, USD
FY 2025
FY 2024
FY 2023
FY 2022
Total Revenues
44,328,000
41,950,000
40,109,000
43,653,000
Cost of Sales
19,319,000
18,706,000
17,975,000
19,142,000
Gross Profit
25,009,000
23,244,000
22,134,000
24,511,000
Selling, General & Administrative Expenses
12,332,000
11,697,000
10,949,000
11,248,000
Depreciation & Amortization Expenses
1,682,000
1,878,000
1,966,000
2,013,000
Research & Development Expenses
2,942,000
2,844,000
2,741,000
2,888,000
Operating Profit
8,053,000
6,825,000
6,478,000
8,362,000
Interest and Investment Income
308,000
344,000
385,000
183,000
Interest Expense
(493,000)
(559,000)
(637,000)
(558,000)
Non-Operating Income
598,000
403,000
438,000
319,000
Total Non-Operating Income
413,000
188,000
186,000
(56,000)
Income Before Provision for Income Taxes
8,466,000
7,013,000
6,664,000
8,306,000
Provision for Income Taxes
1,942,000
(6,389,000)
941,000
1,373,000
Consolidated Net Income
6,524,000
13,402,000
5,723,000
6,933,000
Net Income Attributable to Common Shareholders
6,524,000
13,402,000
5,723,000
6,933,000
Basic EPS
3.73
7.67
3.28
3.94
Diluted EPS
3.72
7.64
3.26
3.91
Basic Weighted Average Shares Outstanding
1,741,000
1,740,000
1,740,000
1,753,000
Diluted Weighted Average Shares Outstanding
1,748,000
1,748,000
1,749,000
1,764,000
Shares Outstanding
1,736,600
1,731,700
1,734,080
1,737,800
FY 2025
FY 2024
FY 2023
FY 2022
Cash and Cash Equivalents
8,522,000
7,616,000
6,896,000
9,882,000
Short-Term Investments
417,000
351,000
383,000
288,000
Total Cash and Cash Equivalents
8,939,000
7,967,000
7,279,000
10,170,000
Accounts Receivable
7,929,000
6,925,000
6,565,000
6,218,000
Other Receivables
2,640,000
2,570,000
2,256,000
2,663,000
Total Trade Receivables
10,569,000
9,495,000
8,821,000
8,881,000
Inventories
6,488,000
6,194,000
6,570,000
6,173,000
Other Current Assets
2,640,000
2,570,000
2,256,000
2,663,000
Total Current Assets
25,996,000
23,656,000
22,670,000
25,224,000
Net Property, Plant & Equipment
37,038,000
33,398,000
32,087,000
29,374,000
Net Intangible Assets
5,526,000
6,647,000
8,815,000
10,454,000
Goodwill
24,035,000
23,108,000
23,679,000
22,799,000
Long-Term Investments
918,000
886,000
799,000
766,000
Other Long-Term Assets
18,422,000
16,459,000
7,097,000
6,033,000
Total Assets
86,713,000
81,414,000
73,214,000
74,438,000
Accounts Payable
4,240,000
4,195,000
4,295,000
4,607,000
Accrued Expenses
7,557,000
6,844,000
7,019,000
7,401,000
Current Portion of Long-Term Debt
3,033,000
1,500,000
1,080,000
2,251,000
Other Current Liabilities
1,666,000
1,618,000
1,447,000
1,230,000
Total Current Liabilities
16,496,000
14,157,000
13,841,000
15,489,000
Long-Term Debt
9,896,000
12,625,000
13,599,000
14,522,000
Other Long-Term Liabilities
7,550,000
6,731,000
6,947,000
7,522,000
Total Long-Term Liabilities
17,446,000
19,356,000
20,546,000
22,044,000
Total Liabilities
33,942,000
33,513,000
34,387,000
37,533,000
Common Stock
25,527,000
25,153,000
24,869,000
24,709,000
Treasury Stock
(17,177,000)
(16,844,000)
(15,981,000)
(15,229,000)
Accumulated Other Comprehensive Income
(6,001,000)
(7,906,000)
(7,839,000)
(8,051,000)
Retained Earnings
49,781,000
47,261,000
37,554,000
35,257,000
Total Common Shareholders' Equity
52,130,000
47,664,000
38,603,000
36,686,000
Minority Interests and Other
641,000
237,000
224,000
219,000
Total Shareholders' Equity
52,771,000
47,901,000
38,827,000
36,905,000
Total Liabilities and Shareholders' Equity
86,713,000
81,414,000
73,214,000
74,438,000
FY 2025
FY 2024
FY 2023
FY 2022
Net Income
6,524,000
13,402,000
5,723,000
6,933,000
Depreciation & Amortization
3,116,000
3,218,000
3,243,000
3,267,000
Share-Based Compensation Expense
664,000
673,000
644,000
685,000
Other Adjustments
65,000
482,000
126,000
215,000
Changes in Trade Receivables
(652,000)
(691,000)
(356,000)
(68,000)
Changes in Inventories
195,000
(58,000)
(232,000)
(1,413,000)
Changes in Accounts Payable
954,000
356,000
(760,000)
420,000
Changes in Income Taxes Payable
(5,000)
(8,028,000)
(585,000)
(383,000)
Changes in Other Operating Activities
(1,295,000)
(796,000)
(542,000)
(75,000)
Cash from Operating Activities
9,566,000
8,558,000
7,261,000
9,581,000
Capital Expenditure
(2,171,000)
(2,207,000)
(2,202,000)
(1,777,000)
Purchases of Investments
(167,000)
(169,000)
(159,000)
(185,000)
Proceeds from Sale of Investments
3,000
28,000
43,000
152,000
Payments for Business Acquisitions
(105,000)
—
(877,000)
—
Proceeds from Business Divestments
—
1,000
40,000
48,000
Other Investing Activities
18,000
9,000
22,000
22,000
Cash from Investing Activities
(2,422,000)
(2,338,000)
(3,133,000)
(1,740,000)
Issuance of Long-Term Debt
5,000
223,000
2,000
7,000
Repayments of Long-Term Debt
(1,504,000)
(660,000)
(2,498,000)
(753,000)
Net Issuance / (Repayments) of Long-Term Debt
(1,499,000)
(437,000)
(2,496,000)
(746,000)
Issuance of Common Shares
396,000
264,000
167,000
167,000
Repurchases of Common Shares
(893,000)
(1,295,000)
(1,227,000)
(3,795,000)
Net Issuance / (Repurchases) of Common Shares
(497,000)
(1,031,000)
(1,060,000)
(3,628,000)
Common Share Dividends Paid
(4,116,000)
(3,836,000)
(3,556,000)
(3,309,000)
Other Financing Activities
(197,000)
(100,000)
21,000
47,000
Cash from Financing Activities
(6,309,000)
(5,404,000)
(7,091,000)
(7,636,000)
Effect of Exchange Rate Changes on Cash and Cash Equivalents
71,000
(96,000)
(23,000)
(122,000)
Increase / (Decrease) in Cash, Cash Equivalents and Restricted Cash